ClearPoint Neuro Announces FDA Clearance of the SmartFrame Array

$ 13.99

5 (558) In stock

Next Generation Neuro Navigation System Designed for Use in Both the MRI Suite and Operating Room ClearPoint SmartFrame Array™ Version 1.1 ClearPoint SmartFrame Array™ Version 1.1 SOLANA BEACH, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it has received FDA clearance for version 1.1 of its next generation SmartFrame Array Neuro Navi
Next Generation Neuro Navigation System Designed for Use in Both the MRI Suite and Operating Room ClearPoint SmartFrame Array™ Version 1.1 ClearPoint SmartFrame Array™ Version 1.1 SOLANA BEACH, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it has received FDA clearance for version 1.1 of its next generation SmartFrame Array Neuro Navi
Next Generation Neuro Navigation System Designed for Use in Both the MRI Suite and Operating Room ClearPoint SmartFrame Array™ Version 1.1 ClearPoint

ClearPoint Neuro, Inc. on LinkedIn: #clearpoint #prism #nsgy #medicaleducation #clpt

ClearPoint Neuro (Nasdaq:CLPT) - Stock Price, News & Analysis - Simply Wall St

Stock Market News 2022-04-28

Brain Tumors Edged Out by Artificial Intelligence: Vysioneer Receives FDA Clearance on First-Ever Tumor Auto-Contouring Solution for Radiation Therapy.

ClearPoint Neuro Stock: Potential Inflection Point (NASDAQ:CLPT)

Katelyn McCray on LinkedIn: ClearPoint Neuro, Inc. strides to

ClearPoint Neuro, Inc. Announces First-in-Human Cases of

ClearPoint Neuro, Inc.

ClearPoint Neuro Stock: Potential Inflection Point (NASDAQ:CLPT)

Mayfield Neurosurgeon Performs 'Asleep Surgery' for Parkinson's at The Jewish Hospital

Katelyn McCray posted on LinkedIn